Pharma BD Deal Intelligence

Novo Nordisk A/S / Kallyope Inc.

2026 · Licensing/Option · Complete

Novo Nordisk licensed three early-stage obesity molecules from Kallyope, comprising a potentially first-in-class therapeutic peptide and two small-molecule candidates. The lead asset is K-554, an IND-ready weekly peptide designed to act on biology distinct from, and potentially complementary to, GLP-1 and amylin receptor agonists. Financial terms were not disclosed. The transaction was first disclosed publicly on 18 September 2026 by Jacob Petersen, head of global research at Novo Nordisk. The companies have partnered since mid-2018 on obesity and diabetes discovery, with Novo exercising an option on one asset under that agreement in September 2024. DATA NOTE: deal value undisclosed; no upfront or milestone figures were published.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Novo Nordisk A/S deals